Emyria (ASX:EMD) has today released compelling insight into the progress of its Post-Traumatic Stress Disorder (PTSD) Program, including interim clinical results for the first eight patients.
Key highlights include:
- Interim analysis of the first eight patients completing Emyria’s MDMA-assisted therapy (MDMA-AT) PTSD program shows all patients achieved substantial improvement in PTSD symptoms, with a clinically and statistically significant average reduction of 33 points in PCL-5 scores.
- All patients reported substantial gains in quality of life.
- Emyria continues to evolve its leading care programs by actively collecting and applying Real-World Data, setting the pace and standards for PTSD care globally.
- Plans are underway to sustainably expand these programs, in close partnership with private hospitals and third-party payers.
These results will be shared in detail by Emyria’s Lead Psychiatrist, Dr Jon Laugharne, at the WA Branch Conference of the Royal Australian and New Zealand College of Psychiatrists (RANZCP) this weekend on 6 and 7 September.
